BioSpace News Archive

Pfizer Inc. and BioNTech SE announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine administered as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history.

Waters Corporation announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Bank of America Global Healthcare Conference in London on Wednesday, September 13th, 2023 at 8:20AM Eastern Time

Oncology Care Partners, an innovative oncology provider built solely to improve the patient experience through value-based care, announces its partnership with CancerX—a public-private partnership to boost innovation in the fight against cancer.

INEX Innovate, a pioneering Women’s Life Science Health Innovations group, is pleased to announce the launch of epiHERA® the company’s early endometrial cancer detection technology. epiHERA® was unveiled at the esteemed 2023 Singapore International Congress of Obstetrics and Gynaecology (SICOG), held from August 25th to 27th.

POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the second quarter and first half of 2023.

Collaboration holds the promise to reduce overtreatment with integrated AI-powered pathology workflows

On August 29, 2023, Broncus Medical (02216.HK), a leader in precise interventional diagnosis and therapy of lung diseases in China, announced its interim results for the six months ended June 30,2023.

Compass Therapeutics, Inc. announced that the Company will participate in the following investor events during the month of September 2023.

Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, announced that management will participate in two upcoming investor conferences.

PTC Therapeutics, Inc. announced that the company will present a company overview at the following conferences.